Description: Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Home Page: www.hillstreambio.com
HILS Technical Analysis
1200 Route 22 East
Bridgewater,
NJ
08807
United States
Phone:
908 955 3140
Officers
| Name | Title |
|---|---|
| Mr. Randy D. Milby MBA | Pres, Chairman & CEO |
| Mr. Thomas P. Hess CPA, MBA | Chief Financial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8831 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-01-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |